International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 001-010
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
The Relationship Between Common EGFR, BRAF, KRAS Mutations and Prognosis in Advanced Stage Non-Small Cell Lung Cancer with Response to the Treatment in Turkey
Mutlu DOGAN1, Ahmet DEMIRKAZIK1, Ajlan TUKUN2,3, Serpil D. SAK4, Koray CEYHAN4, Bulent YALCIN1, Hakan AKBULUT1, Fikri ICLI1
1Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Ankara University Faculty of Medicine, Department of Medical Genetics, Ankara, TURKEY
3Duzen Laboratory Groups, Department of Medical Genetics, Ankara, TURKEY
4Ankara University Faculty of Medicine, Department of Pathology, Ankara, TURKEY
Keywords: Non-Small cell lung cancer, EGFR, KRAS, BRAF, Erlotinib
The aim of the study was to evaluate EGFR (exon 19 deletion, exon 21 L858R point mutation), KRAS and braf mutation rates besides their relationship with survival and response to the treatment in non small cell lung cancer (NSCLC). We evaluated 513 NSCLC patients followed-up between January 2004 and November 2009 according to our registration data, retrospectively. Only 42 advanced stage NSCLC patients had enough tumor tissue material in paraffin blocks for all mutation analysis. The patients were evaluated retrospectively for clinicopathological features, EGFR, KRAS and BRAF mutations, erlotinib treatment, time to progression (TTP) and overall survival (OS). Mutation rates were as 7.14% (two patients) for EGFR exon 19 deletion; 4.76% (one patient)for KRAS codon 61 deletion and 2.38% for BRAF V600E mutation. They had neither EGFR exon 21 point mutation nor different mutations together. Median follow-up was 26 months (5-83) for all patients. It was 43 months (23-83) for the patients who had erlotinib and 23 months (5-61) for those who did not. Ten (23.8%) patients had erlotinib. There was significant survival difference between the patients taking erlotinib and the others (28 ± 3 months versus 15 ± 4 months, p= 0.05). TTP and OS were longer in the patients who had mutations, however the difference was not significant (p= 0.119 and p= 0.06). To our knowledge, this is the first study evaluating EGFR, KRAS and BRAF mutations in advanced stage NSCLC in Turkey .
Mutlu DOGAN1, Ahmet DEMIRKAZIK1, Ajlan TUKUN2,3, Serpil D. SAK4, Koray CEYHAN4, Bulent YALCIN1, Hakan AKBULUT1, Fikri ICLI1
1Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
2Ankara University Faculty of Medicine, Department of Medical Genetics, Ankara, TURKEY
3Duzen Laboratory Groups, Department of Medical Genetics, Ankara, TURKEY
4Ankara University Faculty of Medicine, Department of Pathology, Ankara, TURKEY
Keywords: Non-Small cell lung cancer, EGFR, KRAS, BRAF, Erlotinib
The aim of the study was to evaluate EGFR (exon 19 deletion, exon 21 L858R point mutation), KRAS and braf mutation rates besides their relationship with survival and response to the treatment in non small cell lung cancer (NSCLC). We evaluated 513 NSCLC patients followed-up between January 2004 and November 2009 according to our registration data, retrospectively. Only 42 advanced stage NSCLC patients had enough tumor tissue material in paraffin blocks for all mutation analysis. The patients were evaluated retrospectively for clinicopathological features, EGFR, KRAS and BRAF mutations, erlotinib treatment, time to progression (TTP) and overall survival (OS). Mutation rates were as 7.14% (two patients) for EGFR exon 19 deletion; 4.76% (one patient)for KRAS codon 61 deletion and 2.38% for BRAF V600E mutation. They had neither EGFR exon 21 point mutation nor different mutations together. Median follow-up was 26 months (5-83) for all patients. It was 43 months (23-83) for the patients who had erlotinib and 23 months (5-61) for those who did not. Ten (23.8%) patients had erlotinib. There was significant survival difference between the patients taking erlotinib and the others (28 ± 3 months versus 15 ± 4 months, p= 0.05). TTP and OS were longer in the patients who had mutations, however the difference was not significant (p= 0.119 and p= 0.06). To our knowledge, this is the first study evaluating EGFR, KRAS and BRAF mutations in advanced stage NSCLC in Turkey .
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |